Updated: March 6, 2025
(subject to change)
FRIDAY, APRIL 4, 2025 | ||
10:00-10:30 | Roche Industry Sponsored Speakers' Corner | EXHIBITION AREA |
Rising Stars Debate: AI in Retinal Care: Ready to Enhance Clinical Decisions for Treatment Optimization? | ||
Moderators: | Anat Loewenstein, Israel and Baruch Kuppermann, USA | |
Yes: | ||
No: | ||
12:15–13:15 | Santen Industry Sponsored Luncheon Symposium: How can patient-focused glaucoma management provide individualised treatment beyond IOP control? (Lunch boxes served 12:00–12:15) | HALL A |
Moderator: | Francesca Cordeiro, UK | |
Speakers: | Ernst R. Tamm, Germany; Francesco Oddone, Italy; José Belda, Spain | |
12:15-12:20 | Welcome and introductions Francesca Cordeiro, UK | |
12:20-12:40 | Can underlying structure be used for strategies to provide individualised treatment for IOP control and beyond? Ernst R. Tamm, Germany With debate and panel discussion | |
12:40-12:55 | Can monotherapies deliver additional benefits for individualised treatment beyond IOP control? José Belda, Spain With debate and panel discussion | |
12:55-13:10 | Can understanding what’s behind IOP control shape expectations for individualised treatment? Francesco Oddone, Italy With debate and panel discussion | |
13:10-13:15 | Summary and close Francesca Cordeiro, UK | |
This event is organised and funded by Santen and will contain information on Santen products. | ||
13:30-14:30 | Abbvie Industry Sponsored Dessert Symposium: Patient-centric elevation of standard of care in DME and RVO: 3 discussions (Lunch boxes served 13:15-13:30) | HALL A |
13:30-13:36 | Welcome and introduction Anat Loewenstein, Israel | |
13:36-13:53 13:36-13:41 13:41-13:46 13:46-13:53 | From pathophysiology to clinical practice: Is what you see what you get? Francine Behar-Cohen, France Laurent Kodjikian, France Discussion and Q&A (facilitated by Anat Loewenstein) | |
13:53-14:10 13:53-13:58 13:58-14:03 14:03-14:10 | Should corticosteroids be considered as first-line therapy for DME and RVO? For 1L: Patricia Udaondo, Spain For 2L: Fang Lu, China Discussion and Q&A (facilitated by Anat Loewenstein & Laurent Kodjikian) | |
14:10-14:27 14:10-14:15 14:15-14:20 14:20-14:27 | Clinicians should wait until fluid recurrence before re-treating patients with DME or RVO Thibaud Mathis, France Anat Loewenstein, Israel Discussion and Q&A (facilitated by Laurent Kodjikian) | |
14:27-14:30 | Close and meeting adjournment Anat Loewenstein, Israel | |
17:30-18:30 | Ocular Industry Sponsored Symposium: Advancing Retinal Disease Treatment: Extending Durability with OTX-TKI | HALL A |
Moderator: | Anat Loewenstein, Israel | |
Faculty: | Lloyd Clark, USA and Daniel Martin, USA | |
SATURDAY, APRIL 5, 2025 | ||
COMPANIES LOGOS TO BE INSERTED HERE | ||
07:30-08:30 | Industry Sponsored Breakfast Symposium: On the Horizon Companies (TBC) (Light breakfast will be served from 07:00-07:30 at the entrance of the hall) | HALL A |
Moderators: | Anat Loewenstein, Israel; Baruch Kuppermann, USA | |
10:00-10:30 | Bayer Industry Speakers' Corner | EXHBITION AREA |
Video presentation: Enfocados Documentary - Raising Awareness in DME and wAMD | ||
12:15-13:15 | Bayer Industry Sponsored Luncheon Symposium: Controversies in ophthalmology: spotlight on retinal disease (Lunch boxes served 12:00-12:15) | HALL A |
Chair: | Anat Loewenstein, Israel | |
12:15-12:17 | Welcome and introductions Anat Loewenstein, Israel | |
12:17-12:22 | Our vision in ophthalmology: the latest with aflibercept 8mg Anat Loewenstein, Israel | |
12:22-12:37 | Does aflibercept 8mg provide better drying where it matters? Paolo Lanzetta, Italy | |
12:37-12:52 | Why is aflibercept 8mg a clear choice for treatment-naïve patients? David Brown, USA | |
12:52-13:02 | How can aflibercept 8mg shape your future practice? Patricia Udaondo, Spain | |
13:02-13:12 | Aflibercept 8mg in the clinic: expert perspectives Moderator: Anat Loewenstein, Israel Panel: All Speakers | |
13:12-13:15 | Summary and close Anat Loewenstein, Israel | |
COMPANIES LOGOS TO BE INSERTED HERE | ||
13:30-14:30 | Industry Sponsored Dessert Symposium: On the Horizon Companies (TBC) (Dessert boxes served 13:15 -13:30) | HALL A |
Moderators: | Anat Loewenstein, Israel; Baruch Kuppermann, USA | |
14:30-14:30 | Speakers' Corner Debate: Cost-effectiveness of advanced molecular testing in clinical practice | EXHIBITION AREA |
Faculty: | David Almeida, USA and Vinit B. Mahajan, USA | |